Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Corcept Therapeutics (CORT) over the last 16 years, with Dec 2024 value amounting to $104.8 million.

  • Corcept Therapeutics' Shares Outstanding (Weighted Average) rose 0.84% to $105.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.4 million, marking a year-over-year increase of 0.84%. This contributed to the annual value of $104.8 million for FY2024, which is 1.64% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Shares Outstanding (Weighted Average) of $104.8 million as of FY2024, which was up 1.64% from $103.1 million recorded in FY2023.
  • Over the past 5 years, Corcept Therapeutics' Shares Outstanding (Weighted Average) peaked at $116.2 million during FY2020, and registered a low of $103.1 million during FY2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $105.2 million, with a median of $104.8 million in 2024.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first climbed by 1.66% in 2020, then declined by 6.76% in 2022.
  • Corcept Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $116.2 million in 2020, then declined by 0.62% to $115.5 million in 2021, then declined by 6.76% to $107.6 million in 2022, then dropped by 4.24% to $103.1 million in 2023, then climbed by 1.64% to $104.8 million in 2024.